Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MYL9 CRISPR/Cas9 KO Plasmid (h): sc-401577
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MYL9 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MYL9 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MYL9 CRISPR/Cas9 KO Plasmid (h) | sc-401577 | 20 µg | $397.00 |
Overview
MYL9 encodes myosin light chain 9, a regulatory light chain that modulates actin–myosin contractility by controlling myosin II motor activity. Its phosphorylation state integrates signaling through Ca²⁺/calmodulin-dependent myosin light chain kinase and RhoA–ROCK pathways to regulate stress fiber formation, focal adhesion dynamics, and cell shape changes. MYL9 contributes to smooth muscle contraction as well as non-muscle processes including cytokinesis, cell migration, and endothelial or fibroblast contractile responses. Dysregulated MYL9-linked contractility and cytoskeletal remodeling have been associated with altered vascular tone, tissue fibrosis, and invasive cell behaviors relevant to cancer biology.
MYL9 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MYL9 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MYL9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MYL9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MYL9 protein expression.
This CRISPR knockout system enables efficient generation of MYL9-deficient cell models for investigation of MYL9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MYL9 exon(s) critical for MYL9 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MYL9 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MYL9 CRISPR/Cas9 KO Plasmid (h) and MYL9 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MYL9 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MYL9 HDR Plasmid (h) and MYL9 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MYL9 homology arms to support homology-directed repair at defined MYL9 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.